- Conditions
- Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection
- Interventions
- Valganciclovir, Ganciclovir (GCV), Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 21, 2026, 7:41 PM EDT